# ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

> **NCT00879229** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 40 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension

## Interventions

- **DRUG:** Ambrisentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00879229
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00879229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00879229, "ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00879229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*